CLINICAL TRIALS PROFILE FOR BELSOMRA
✉ Email this page to a colleague
All Clinical Trials for Belsomra
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02491788 ↗ | Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2016-02-01 | The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep. |
| NCT02491788 ↗ | Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers | Completed | Stanford University | Phase 4 | 2016-02-01 | The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep. |
| NCT02491788 ↗ | Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers | Completed | VA Palo Alto Health Care System | Phase 4 | 2016-02-01 | The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep. |
| NCT02527564 ↗ | Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder | Recruiting | Merck Sharp & Dohme Corp. | Phase 4 | 2015-09-01 | The purpose of this study is to evaluate the efficacy of suvorexant, added to existing medications, for treatment-resistant insomnia in individuals with bipolar disorder. The investigators hypothesize that participants receiving suvorexant for one week will experience significantly greater improvement in sleep duration compared to participants receiving placebo. |
| NCT02527564 ↗ | Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder | Recruiting | Stanford University | Phase 4 | 2015-09-01 | The purpose of this study is to evaluate the efficacy of suvorexant, added to existing medications, for treatment-resistant insomnia in individuals with bipolar disorder. The investigators hypothesize that participants receiving suvorexant for one week will experience significantly greater improvement in sleep duration compared to participants receiving placebo. |
| NCT02669030 ↗ | A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia | Unknown status | Augusta University, Dept. of Psychiatry | Phase 4 | 2017-03-01 | Depression with ongoing insomnia is a common clinical presentation with patients. Clinical data suggests that patients with insomnia that receive concomitant treatment with a sleep aid experience a more robust antidepressant response along with a quicker response. The purpose of this clinical study is to compare the effectiveness of the FDA-approved insomnia medication suvorexant, also known as Belsomra®, as add-on treatment to an antidepressant to that of placebo plus antidepressant treatment in patients with depression and residual or ongoing insomnia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Belsomra
Condition Name
Clinical Trial Locations for Belsomra
Trials by Country
Clinical Trial Progress for Belsomra
Clinical Trial Phase
Clinical Trial Sponsors for Belsomra
Sponsor Name
